In people with insulin resistance or type 2 diabetes, skeletal muscle has fewer mitochondria and reduced ability to produce energy using oxygen, which correlates with lower levels of PGC-1α and related proteins that regulate mitochondrial production.
See the scientific wording
Reduced mitochondrial biogenesis, mediated by decreased expression of PGC-1α and related transcription factors, is associated with lower mitochondrial density and impaired oxidative capacity in skeletal muscle of individuals with insulin resistance and type 2 diabetes.
Correlational — new studies may shift this
One low-scoring study links this claim to the outcome, but causation is not established.
What the research says
1 study reviewedSupporting (1)
Role of mitochondrial dysfunction in insulin resistance.
Narrative ReviewReview2008
In people with insulin resistance or type 2 diabetes, their muscle cells don’t make enough new energy factories (mitochondria), so they can’t burn fuel well—this study says that’s a key reason why their bodies struggle with blood sugar control.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
When the body's energy sensors detect low energy use, they normally turn on a master switch called PGC-1α that tells cells to make more energy-producing factories called mitochondria. In insulin-resistant people, this switch stays off, so fewer mitochondria are made. The mitochondria that exist are smaller and less able to burn fuel, causing fat buildup and toxic byproducts that block insulin's signal. This prevents muscle cells from taking in sugar, raising blood sugar levels.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
In people with insulin resistance or type 2 diabetes, skeletal muscle has fewer mitochondria and reduced ability to produce energy using oxygen, which correlates with lower levels of PGC-1α and related proteins that regulate mitochondrial production.
Mechanism
1 studyWhen the body doesn't use enough energy, it normally makes more energy factories called mitochondria using a master switch called PGC-1α. In insulin-resistant people, this switch is turned off, so mitochondria don't multiply or work well. This causes fat buildup and toxic byproducts that block insulin from working, so sugar stays in the blood instead of entering muscle cells.
When the body's energy sensors detect low energy use, they normally turn on a master switch called PGC-1α that tells cells to make more energy-producing factories called mitochondria. In insulin-resistant people, this switch stays off, so fewer mitochondria are made. The mitochondria that exist are smaller and less able to burn fuel, causing fat buildup and toxic byproducts that block insulin's signal. This prevents muscle cells from taking in sugar, raising blood sugar levels.
PGC-1α expression is reduced due to chronic nutrient excess, aging, or reduced eNOS/NO signaling
Reduced PGC-1α fails to coactivate NRF-1 and PPAR-α/γ, decreasing transcription of mitochondrial genes
NRF-1 downregulates expression of TFAM and oxidative phosphorylation subunits, impairing mitochondrial DNA replication and protein synthesis
Mitochondrial biogenesis is suppressed, resulting in fewer and smaller mitochondria with reduced oxidative capacity
Impaired electron transport chain function increases mitochondrial reactive oxygen species production due to high proton-motive force and low ATP demand
Excess mitochondrial reactive oxygen species activate serine/threonine kinases including IKKβ, JNK, and PKCθ
Serine phosphorylation of IRS-1/2 inhibits insulin receptor signaling and downstream PI3K/Akt activation
Reduced insulin signaling decreases GLUT4 translocation and glucose uptake in skeletal muscle and impairs suppression of hepatic glucose production
Less supported by current evidence, but not ruled out
High levels of angiotensin II trigger an enzyme called NADPH oxidase to produce reactive oxygen species, which directly damage mitochondria and reduce their ability to generate energy. This damage worsens insulin resistance by impairing fuel burning and promoting fat accumulation.
Angiotensin II binds to AT1 receptors on skeletal muscle and liver cells
AT1 receptor activation stimulates NADPH oxidase to generate superoxide
NADPH oxidase-derived superoxide damages mitochondrial membranes and respiratory complexes
Mitochondrial damage reduces ATP synthesis and β-oxidation, increasing lipid intermediates
Accumulated lipid intermediates and ROS inhibit insulin signaling through serine phosphorylation of IRS-1
When calorie intake is consistently high, levels of a molecule called NAD+ drop, which turns off SIRT1. Without SIRT1, PGC-1α remains inactive because it is not properly modified, preventing the cell from making new mitochondria even when energy demand is high.
Chronic nutrient excess reduces cellular NAD+ levels
Low NAD+ decreases SIRT1 deacetylase activity
PGC-1α remains acetylated and transcriptionally inactive
Inactive PGC-1α fails to drive NRF-1 and TFAM expression, suppressing mitochondrial biogenesis
In the insulin-producing cells of the pancreas, damaged mitochondria cannot generate enough energy from sugar, which prevents the cells from releasing insulin when blood sugar rises. This lack of insulin release worsens high blood sugar and contributes to type 2 diabetes.
Glucose metabolism in β-cells fails to generate sufficient ATP due to mitochondrial dysfunction
Low ATP/ADP ratio prevents closure of KATP channels on the β-cell membrane
Failure to depolarize the membrane blocks calcium influx
Calcium-dependent insulin exocytosis is impaired, reducing insulin secretion
Evidence from Studies
Supporting (1)
Community contributions welcome
Role of mitochondrial dysfunction in insulin resistance.
In people with insulin resistance or type 2 diabetes, their muscle cells don’t make enough new energy factories (mitochondria), so they can’t burn fuel well—this study says that’s a key reason why their bodies struggle with blood sugar control.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
Clinical support requires direct evidence. Mechanistic proxy and tangential studies contribute only to the mechanistic score.
- All linked studies are tangential or mechanistic proxies — no direct test of the claim has been found.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review of Mitochondrial Biogenesis Markers and Oxidative Capacity in Insulin Resistance and Type 2 Diabetes
Population: Adults with diagnosed insulin resistance or type 2 diabetes; Intervention: None (observational); Comparator: Healthy controls; Outcome: Mitochondrial density (via electron microscopy or citrate synthase activity), oxidative capacity (via VO2 max or muscle respirometry), and PGC-1α expression levels (via qPCR or Western blot); Duration: N/A (aggregate of existing studies).
Longitudinal Cohort Study of PGC-1α Expression, Mitochondrial Density, and Oxidative Capacity in Prediabetic and Diabetic Individuals
Population: Adults with prediabetes and early type 2 diabetes; Intervention: None (observational); Comparator: Individuals who remain normoglycemic; Outcome: Serial measurements of PGC-1α expression, mitochondrial density (muscle biopsy), and oxidative capacity (indirect calorimetry) over 3–5 years; Duration: 3–5 years.
Cross-Sectional Analysis of PGC-1α Expression, Mitochondrial Density, and Oxidative Capacity in Skeletal Muscle of Diabetic vs. Non-Diabetic Adults
Population: Adults with insulin resistance or type 2 diabetes and age-matched healthy controls; Intervention: None; Comparator: Healthy controls; Outcome: Single-timepoint measurements of PGC-1α mRNA/protein, mitochondrial density (electron microscopy), and oxidative capacity (muscle biopsy respirometry); Duration: Single visit.
In Vitro Knockdown of PGC-1α in Human Skeletal Muscle Myotubes and Measurement of Mitochondrial Biogenesis and Oxidative Capacity
Population: Primary human skeletal muscle myotubes derived from healthy donors; Intervention: siRNA-mediated knockdown of PGC-1α; Comparator: Non-targeting siRNA control; Outcome: Mitochondrial content (MTT assay, mitochondrial DNA copy number), oxidative capacity (Seahorse analyzer), and expression of downstream transcription factors; Duration: 48–72 hours.
PGC-1α Knockout Mouse Model: Assessment of Skeletal Muscle Mitochondrial Density and Oxidative Capacity in Insulin-Resistant Conditions
Population: Wild-type and PGC-1α knockout mice; Intervention: High-fat diet to induce insulin resistance; Comparator: Wild-type mice on normal diet; Outcome: Mitochondrial density (electron microscopy), oxidative enzyme activity (SDH, COX), and muscle respiration (high-resolution respirometry); Duration: 12–16 weeks.